LONDON—Hematopoietic stem cells are not displaced and depleted by malignant cells in patients with acute myeloid leukaemia but merely put to sleep, according to research from London published in PNAS Early Edition. Professor John Gribben from Barts Cancer Institute in London discusses their finding and explains how this gives new opportunities for treating AML.
You may also like...
Chimeric antigen receptor T-cell therapy: high remission rate in relapsed, refractory acute lymphoblastic leukemia 19 Dec, 2013 Gender Disparity in Head and Neck Cancer Treatment and Outcomes 9 Jun, 2018 Second-Generation ALK Inhibitor = Longer PFS in ALK+ Lung Cancer After Crizotinib 8 Dec, 2016 Two-step immunotherapy brings promise in advanced ovarian cancer 8 Apr, 2013
- Previous story Chimeric antigen receptor T-cell therapy rescues kids with relapsing acute lymphoblastic leukaemia
- Next story Normal stem cells are not depleted in acute myeloid leukaemia and could be targeted therapeutically
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014